Main characteristics of PTCL patients
| Non-ALCL patients . | . | . | . |
|---|---|---|---|
| Characteristic . | PTCL nos (n = 26) . | AITL (n = 46) . | Total cohort (N = 78) . |
| Median age at diagnosis, y | 74 | 65 | 66 |
| Male: female ratio | 14:12; 1,2 | 28:18; 1,55 | 47:31; 1,52 |
| Stage | |||
| I | 2/26 | 1/46 | 3/78 |
| II | 1/26 | 1/46 | 2/78 |
| III | 7/26 | 11/46 | 18/78 |
| IV | 16/26 | 32/46 | 55/78 |
| NC | 0/26 | 1/46 | 1/78 |
| Elevated serum LDH, % (n/N) | 73,1 | 76,7 | 75 |
| IPI score | |||
| 0 | 3 | 1 | 4 |
| 1 | 2 | 1 | 3 |
| 2 | 3 | 7 | 12 |
| 3 | 8 | 8 | 18 |
| 4 | 5 | 15 | 22 |
| 5 | 3 | 9 | 13 |
| NC | 2 | 5 | 7 |
| OS of total cohort, % (n/N) | |||
| 1 y | 58,2 | ||
| 3 y | 40,5 | ||
| PFS of total cohort, % (n/N) | |||
| 1 y | 43 | ||
| 3 y | 24 | ||
| Patients receiving chemotherapy, % (n/N) | 98,7 | ||
| Non-ALCL patients . | . | . | . |
|---|---|---|---|
| Characteristic . | PTCL nos (n = 26) . | AITL (n = 46) . | Total cohort (N = 78) . |
| Median age at diagnosis, y | 74 | 65 | 66 |
| Male: female ratio | 14:12; 1,2 | 28:18; 1,55 | 47:31; 1,52 |
| Stage | |||
| I | 2/26 | 1/46 | 3/78 |
| II | 1/26 | 1/46 | 2/78 |
| III | 7/26 | 11/46 | 18/78 |
| IV | 16/26 | 32/46 | 55/78 |
| NC | 0/26 | 1/46 | 1/78 |
| Elevated serum LDH, % (n/N) | 73,1 | 76,7 | 75 |
| IPI score | |||
| 0 | 3 | 1 | 4 |
| 1 | 2 | 1 | 3 |
| 2 | 3 | 7 | 12 |
| 3 | 8 | 8 | 18 |
| 4 | 5 | 15 | 22 |
| 5 | 3 | 9 | 13 |
| NC | 2 | 5 | 7 |
| OS of total cohort, % (n/N) | |||
| 1 y | 58,2 | ||
| 3 y | 40,5 | ||
| PFS of total cohort, % (n/N) | |||
| 1 y | 43 | ||
| 3 y | 24 | ||
| Patients receiving chemotherapy, % (n/N) | 98,7 | ||
Total cohort of non-ALCL patients included 6 rare diagnostics (HSTL, NK/T, and EATL).
NC indicates not communicated; and LDH, lactate dehydrogenase.